Items where authors include "Wilson, RH"

Article

Brown, LC, Graham, J, Fisher, D et al. (15 more authors) (2022) Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 19 (2). pp. 146-157. ISSN 1740-7745

Seligmann, JF, Fisher, DJ, Brown, LC et al. (19 more authors) (2021) Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring. Journal of Clinical Oncology, 39 (33). pp. 3705-3715. ISSN 0732-183X

Adams, RA, Fisher, DJ, Graham, J et al. (19 more authors) (2021) Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. Journal of Clinical Oncology. JCO.21.01436-JCO.21.01436. ISSN 0732-183X

Loughrey, MB, Webster, F, Arends, MJ et al. (13 more authors) (2021) Dataset for pathology reporting of colorectal cancer: recommendations from the International Collaboration on Cancer Reporting (ICCR). Annals of Surgery. ISSN 0003-4932

Lawler, M, Alsina, D, Adams, RA et al. (18 more authors) (2018) Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. Gut, 67 (1). pp. 179-193. ISSN 0017-5749

Maughan, TS, Meade, AM, Adams, RA et al. (22 more authors) (2014) A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine? British Journal of Cancer, 110 (9). 2178 - 2186. ISSN 0007-0920

Madi, A, Fisher, D, Wilson, RH et al. (9 more authors) (2012) Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial. British Journal of Cancer, 107 (7). pp. 1037-1043. ISSN 0007-0920

Conference or Workshop Item

Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.

Adams, R, Fisher, D, Graham, J et al. (13 more authors) (2021) Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial. In: 2021 ASCO Annual Meeting I, 04-08 Jun 2021, Online.

Proceedings Paper

Shiu, K-K, Seligmann, JF orcid.org/0000-0003-4379-6005, Graham, J et al. (15 more authors) (2022) NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumor mutation burden for high-risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer. In: Journal of Clinical Oncology. 2022 ASCO Annual Meeting I, 03-07 Jun 2022, Chicago, USA. American Society of Clinical Oncology .